In mouse models of GBM, TanCAR T cells targeting HER2 and IL13Ra2 have demonstrated the ability to mitigate antigen escape, resulting in enhanced antitumor efficacy and improved survival outcomes [48]. This evidence concerns the gene ERBB2 and glioblastoma.